MarketCap
Facebook
X
Telegram
Synthetic Biologics EV - Enterprise Value | SYN
Annual EV - Enterprise Value Synthetic Biologics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.8 M | 5.97 M | -7.04 M | -9.77 M | -59.4 M | 11.9 M | -749 K | -21.3 M | 67.3 M | 79.5 M | 123 M | 96.7 M | 73.2 M | 55 M | 53.6 M | -2.12 M | -2.72 M |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 123 M | -59.4 M | 27.8 M |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Xenon Pharmaceuticals
XENE
|
2.24 B | $ 39.02 | 3.56 % | $ 3.09 B |  Canada |
 |
Leap Therapeutics
LPTX
|
-4.36 M | - | 368.57 % | $ 41.9 M |  USA |
 |
Zymeworks
ZYME
|
783 M | $ 29.63 | 3.1 % | $ 1.53 B | Canada |
 |
Adial Pharmaceuticals
ADIL
|
-3.17 M | $ 3.15 | -35.42 % | $ 2.11 M | USA |
 |
ADMA Biologics
ADMA
|
3.84 B | $ 12.73 | -3.67 % | $ 3.03 B | USA |
 |
Cortexyme
CRTX
|
123 M | - | -1.05 % | $ 67.1 M | USA |
 |
Burford Capital Limited
BUR
|
5.73 B | $ 3.6 | -9.22 % | $ 789 M |  Britain |
 |
Daré Bioscience
DARE
|
21.8 M | $ 0.64 | 2.96 % | $ 7.15 M | USA |
 |
Fate Therapeutics
FATE
|
140 M | $ 1.84 | -0.54 % | $ 219 M | USA |
 |
Greenwich LifeSciences
GLSI
|
386 M | $ 15.15 | 3.41 % | $ 205 M | USA |
 |
Halozyme Therapeutics
HALO
|
12 B | $ 103.85 | -15.54 % | $ 12.4 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
12.4 B | $ 15.16 | 6.76 % | $ 13 B |  China |
 |
Aptorum Group Limited
APM
|
8.14 M | - | - | $ 5.72 M | China |
 |
iBio
IBIO
|
98.5 M | $ 0.74 | 0.77 % | $ 77 M | USA |
 |
Kodiak Sciences
KOD
|
2.01 B | $ 99.33 | 9.13 % | $ 5.29 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
341 M | $ 0.05 | -14.81 % | $ 547 | USA |
 |
FSD Pharma
HUGE
|
4.15 M | - | 5743.5 % | $ 69.7 M | Canada |
 |
BioAtla
BCAB
|
52.3 M | $ 1.74 | 0.64 % | $ 102 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
2.48 B | - | - | $ 3.85 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
1.12 B | $ 24.77 | -3.73 % | $ 1.19 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
986 M | $ 13.47 | 4.1 % | $ 1.2 B | USA |
 |
ARCA biopharma
ABIO
|
-30.2 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-14.2 M | - | 4.01 % | $ 150 M | Canada |
 |
ADiTx Therapeutics
ADTX
|
9.4 M | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
10.3 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
3.93 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
9.53 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
4.02 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-55.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
3.01 B | - | - | $ 5.18 B | USA |
 |
Athira Pharma
ATHA
|
-4.92 M | - | - | $ 269 M | USA |
 |
Avenue Therapeutics
ATXI
|
-1.76 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
-244 M | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
59.6 B | - | - | $ 96.9 B | Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-720 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
EyePoint Pharmaceuticals
EYPT
|
-42.8 M | $ 0.36 | 0.59 % | $ 26.4 K | USA |
 |
Bio-Path Holdings
BPTH
|
10.3 M | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
-9.61 M | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
-34.9 M | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
-12.8 M | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-2.16 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-2.16 M | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
-3.58 M | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
41.9 M | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
17.3 M | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
1.16 B | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
89.1 M | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
4.26 M | - | 49.81 % | $ 13.2 M | USA |